The 9th International Workshop on Waldenstrom's Macroglobulinemia and Symposium on Advances in Multiple Myeloma was held October 5-8, 2016 at the Renaissance Hotel and Koepelkerk Convention Ctr. in Amsterdam, The Netherlands.  The following are the 8 posters presented by the Bing Center for Waldenstrom's Macroglobulinemia.  Click on the poster to download a full size PDF version.

Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells that is Accompanied by ERK1/2 Hyperactivation, and is Targeted by the Addition of the ERK1/2 Inhibitor Ulixertinib.

Chen JG, Liu X, Chen J, Xu L, Tsakmaklis N, Demos M, Patterson CJ, Castillo JJ, Hunter ZR, Treon SP, Yang G.


Lower doses of bendamustine are not associated with worse response rates in patients with Waldenström macroglobulinemia

Joshua N. Gustine, Kirsten Meid, Toni Dubeau, Steven P. Treon, Jorge J. Castillo


 The high risk of symptomatic hyperviscosity in patients with high serum IgM levels can be used to support initiation of treatment in Waldenström macroglobulinemia

Joshua N. Gustine, Kirsten Meid, Robert Manning, Toni Dubeau, Irene M. Ghobrial, Steven P. Treon, and Jorge J. Castillo.


Ixazomib, dexamethasone and rituximab (IDR) as primary therapy for symptomatic Waldenström macroglobulinemia

Jorge J. Castillo, Kirsten Meid, Joshua N. Gustine, Toni Dubeau, Xu Yang G, Zachary Hunter, Steven P. Treon


Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenström macroglobulinemia

Kirsten Meid, Christina Tripsas, Leonard Heffner, Herbert Eradat, Ashraf Z. Badros, Lian Xu, Zachary R. Hunter, Guang Yang, Christopher J. Patterson, Joshua Gustine, Jorge J. Castillo, Jeffrey Matous, Irene M. Ghobrial, and Steven P. Treon


Chromosome 6q deletions are common in Waldenström’s Macroglobulinemia, and target regulatory genes for MYD88, CXCR4 and BCL2 signaling

Maria Luisa Guerrera, MD, Nicholas Tsakmaklis, Lian Xu, MS, Guang Yang, PhD, Robert R Manning, Maria Demos, Christopher J Patterson, MFA, Jorge J Castillo, MD, Toni Dubeau, NP, Joshua Gustine, MPH, Xia Liu, MD, Jie Chen, PhD, Jiaji G Chen, Luca Arcaini, MD, Marzia Varettoni, MD, Mario Cazzola, MD, Steven P Treon, MD, PhD and Zachary Hunter, PhD


Mutated MYD88 homozygosity is increased in previously treated patients with Waldenstrom’s Macroglobulinemia and associates with CXCR4 mutation status

Nickolas Tsakmaklis, Lian Xu, Guang Yang, Jie Chen, Xia Liu, Jiaji Chen, Maria Demos, Christopher J. Patterson, Jorge Castillo, Steven P. Treon and Zachary R. Hunter


HCK Transcription is Regulated by AP1, NF-kB and STAT3 Transcription Factors in MYD88 Mutated WM and ABC-DLBCL Cells.

Liu X, Chen JG, Chen J, Xu L, Tsakmaklis N, Demos M, Patterson CJ, Castillo JJ, Hunter ZR, Treon SP, Yang G.